AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06177951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NICU Infant Care Class
Description: The class will be provided once or twice weekly to eligible study participants. It will be conducted in a small group format. Class teachers will focus on providing key anticipatory guidance to aid in the transition home during the first month of life . Topics related to infant care will be discussed, including feeding, elimination, skincare, hygiene, soothing, development, and when to see a doctor/emergencies.
Study NCT04591379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influenza Vaccines
Description: Intratumoral application of an unattenuated influenza vaccine
Study NCT05011877 — intervention group
Intervention type: DEVICE
Intervention: High-flow nasal cannula therapy
Description: High-flow nasal cannula therapy (HFNC) (from 25 - 60 L/min based on patient's tolerance) will be used in 21 participants during one additional sleep study to investigate its acute impact on reducing sleep abnormalities. Inspired fraction of oxygen will be titrated to maintain patient SpO2 similar to the levels during standard oxygen therapy.
Study NCT05527899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zinc gluconate
Description: 30 and 60 mg/d of zinc gluconate
Study NCT05527899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Description: 30 and 60 mg/d of zinc gluconate
Study NCT05541913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele nursing
Description: The intervention group in the study will be the parents of children who received routine care in the surgical service and who received tele-nursing service, who had undergone circumcision operation.After the admission of the child in the service, the Beck Anxiety Scale will be applied to measure the anxiety levels of the parents at the first hospitalization. After the routine discharge training in the service, the Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again. Then, the parents will be called on the 1st postoperative day and training will be provided. On the postoperative 2nd, 3rd and 4th days, counseling will be provided. on the postoperative 4th day Parents will be asked to fill in the Beck Anxiety sScale and Health Care Satisfaction scale.
Study NCT06323967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Large unconditional cash transfers plus voluntary peer support.
Description: These participants will receive monthly cash transfers of $1,500 ($750 twice per month) via debit card for 24 months and can elect to participate in peer support services plus usual care from shelter staff.
Study NCT06323967 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nominal cash transfers
Description: These participants will receive monthly cash transfers of $50 via debit card for 24 months plus usual care from shelter staff.
Study NCT06323967 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Passive comparison group
Description: These families will receive usual care from shelter staff. They will be followed anonymously in administrative records only.
Study NCT06161337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meals
Description: Each subject will participate in 4 visits with a 1-week washout period in between visits.~Each visit will be either a morning or evening consumption of either a standardized mixed meal of containing 600 calories (standard control) or 2400 calories (overeating meal) - meals will have the same nutrient composition.
Study NCT06059599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active informed consent
Description: new preoperative information method, based on multimedia tools and on the objective control of understanding by the patient candidate for vertebral or urological surgery.
Study NCT05334043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CuminUP30
Description: 7 capsules, 500 mg / capsule
Study NCT05334043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin capsules
Description: 5 capsules, 450 mg / capsule
Study NCT05624190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA)
Description: The administration of rhTNK-tPA will be infused constant and slowly over 15min (0.125 mg/kg, Max 12.5mg) through a microcatheter.
Study NCT05624190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Medical Management
Description: Best Medical Management
Study NCT05624190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Management
Description: Best Medical Management
Study NCT04781270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI regimen
Description: oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
Study NCT04781270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX regimen
Description: oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
Study NCT04781270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg on day 1
Study NCT04781270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg on day 1
Study NCT05306743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONQUEST Quality Improvement Program
Description: CONQUEST supports primary healthcare professionals to diagnose, assess, and optimize the management of their patients with modifiable high-risk COPD, through the promotion of guideline-based care. CONQUEST will promote management according to four Quality Standards for the care of modifiable high-risk COPD patients. The Quality Standards can be summarized as the timely and appropriate: Identification of high-risk patient groups for assessment; Assessment of disease and quantification of future risk; Non-pharmacological and pharmacological intervention; Follow-up. CONQUEST program will promote adherence to these standards through the use of electronic medical record -based algorithms for the identification of high-risk patients and clinical decision support resources. All decisions regarding patient management are made entirely at the discretion of the clinicians and patients who together negotiate the preferred course of action during consultations.
Study NCT05306743 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CONQUEST Quality Improvement Program
Description: CONQUEST supports primary healthcare professionals to diagnose, assess, and optimize the management of their patients with modifiable high-risk COPD, through the promotion of guideline-based care. CONQUEST will promote management according to four Quality Standards for the care of modifiable high-risk COPD patients. The Quality Standards can be summarized as the timely and appropriate: Identification of high-risk patient groups for assessment; Assessment of disease and quantification of future risk; Non-pharmacological and pharmacological intervention; Follow-up. CONQUEST program will promote adherence to these standards through the use of electronic medical record -based algorithms for the identification of high-risk patients and clinical decision support resources. All decisions regarding patient management are made entirely at the discretion of the clinicians and patients who together negotiate the preferred course of action during consultations.
Study NCT05301998 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin and thickness measurement/breast MRI
Description: Patient will be installed in dorsal decubitus position. Measurements will be performed at 3 sites on one breast: at the areola, above the areola and below. Measurements will be performed by a single gynecologist using a cutometer provided by TIMC-IMAG laboratory of Grenoble. Three measurements will be performed at each site. Duration of measurements will be approximately 15 minutes.~Measurement of skin thickness will be performed using an ultrasound device available in obstetrics/gynecology consultation department. The measurement will be performed at 3 sites. The duration of the measurements will be of approximately 10 minutes.~Among the 200 patients, 10 patients who should benefit from a breast MRI as part of their follow-up, will have a breast MRI in 3 different positions: prone (standard protocol) and two additional acquisitions (as part of the research) in dorsal and right lateral decubitus. This examination will be scheduled in the senology department of the Lapeyronie Hospital
Study NCT04258683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients not progressing after 2 cycles of CyBorD treatment and achieving less than VGPR by IMWG criteria will be screened to receive pembrolizumab intravenously at 200mg at day 1 of every 3-week cycle for 8 cycles (24 weeks) starting Cycle 4 of CyBorD. CyBorD will be discontinued after 24 weeks and pembrolizumab will be administered as a single agent at the same dose for an additional 27 cycles (81 weeks).
Study NCT05233709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: FeSO4 + OTf
Description: OTf (apo ovotransferrin) + FeSO4
Study NCT05233709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: FeSO4 + Lf
Description: Lf (lactoferrin) + FeSO4
Study NCT05233709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: FeSO4
Description: Ferrous sulfate
Study NCT05360628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120 in combination with Allopurinol
Description: noted above
Study NCT05772611 — intervention group
Intervention type: BIOLOGICAL
Intervention: Genetic and immunology tests
Description: This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF, cells). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes.
Study NCT04966819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survivorship Care Initiative
Description: The survivorship initiative will consist of:~(A) Regular meetings with the rectal cancer oncology pivot nurse (IPO). These meetings present an opportunity for patients to discuss any treatment-related distress or late and long-term side-effect.~(B) Identification of a primary care physician. If the patient is not known to a Primary care physician (PCP), the IPO will add the patient to an accelerated waitlist.~(C) Development of an individualized survivorship plan. During meetings with the oncology pivot nurse, a survivorship care plan will be populated, included information on patient risk factors, treatments completed, pathology findings, and future surveillance planned. This document will be reviewed by the treating colorectal surgeon, and will be subsequently shared with the oncology team, the PCP and the patient (if the patient desires).~(D) Educational resources for patients. Patients will be offered educational materials to help address their specific needs.
Study NCT05158842 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Adult bubble CPAP oxygen therapy device
Description: In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the patient. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the patient. Oxygen is delivered by a successfully tested, silicon-based, ergonomically designed adaptive version of nasal canula (nasal seal) inserted into the nostril of a patient.~The components are:~1. Adaptive version of nasal canula (nasal seal)~2. A nasal canula with connecting circuit system~3. Water-filled bottle with marking water pressure from10 to15 L/min.~Oxygen cylinder, central distribution through pipelines or by oxygen concentrator will be used as an oxygen source.
Study NCT06222242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mychoiceTM
Description: mychoiceTM is an online, educational tool designed to help prepare patients for a conversation with their provider about clinical trials as a treatment option. It consists of text, animations, and videos of real cancer patients sharing their experience with clinical trials. It is not meant to be a recruitment tool, but rather a preparatory tool to promote shared decision making between patients and providers.
Study NCT06319183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: We will recruit at least 15 male and 15 female volunteers, dividing study participants into two groups based on sex. Before administration, the temperature of the brown adipose tissue area in the scapular region of participants will be recorded using an infrared thermometer. Subsequently, participants will inhale the asthma medication salbutamol according to the safe dosage requirements (100ug). Eight hours later, the temperature changes in the brown adipose tissue area in the scapular region will be detected using an infrared thermometer. During the 8-hour waiting period, the participants' heart rate and blood pressure will be monitored; finally, we will draw 1 milliliter of venous blood from the arm of the participants for blood component analysis. The single trial process will last up to 8 hours, with no follow-up required.
Study NCT06553963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: The control group maintained their regular diet and training without additional nutritional support.
Study NCT04814498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geneva Cocktail
Description: Fixed sequence use of drug cocktail
Study NCT04814498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-0409
Description: Fixed sequence use of active product
Study NCT04535245 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LCI testing
Description: all subjects will have LCI testing then contacted via a phone interview or EMR review yearly times 5 to determine if they have subsequently developed ILD
Study NCT06098053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: Muscle energy technique is used at a rate of three sessions per week for four and half weeks
Study NCT06098053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscel energy technique along with interferential therapy
Description: Muscle energy technique along with interferential therapy is used at a rate of three sessions per week for four and half weeks
Study NCT05614518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride F-18 Injection
Description: Each subject was given 5-10 mCi intravenously. Images were collected 90-120 min after injection.
Study NCT05614518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Technetium[99mTc] Methylenediphosphonate Injection
Description: Each subject was given 10-25 mCi intravenously. Images were collected 3-6 hours after injection.
Study NCT05849623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Mucosal Resection (EMR)
Description: EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
Study NCT05849623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Endoscopic Mucosal Resection (C-EMR)
Description: C-EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
Study NCT05849623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Underwater Endoscopic Mucosal Resection (U-EMR)
Description: U-EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
Study NCT04978090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed EAF management device
Description: Participants will receive a customized 3D printed device based on the EAF's output, size, shape, location, depth, and the participant's wound bed.
Study NCT06520891 — intervention group
Intervention type: DRUG
Intervention: Statin and SGLT2i
Description: Statin as atrovastatin SGLT2i as dapagliflozin
Study NCT06366412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: dexmedetomidine effect in preventing postoperative cognitive dysfunction on elderly patients undergoing major surgery guided with serum Tau-217 protein.
Study NCT06366412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline will be administrated in placebo group
Study NCT05271968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Global management of scabies
Description: For the interventional arm, the first course of the oral treatment has also to be swallowed at the BOPC service, but the patient will have to come back the following day to take a shower at the BOPC service and will receive new clothes.~The second course will be given, but the patient will have to come back the following day of the second course to take a shower at the BOPC service and to receive again new clothes
Study NCT06553963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Biochemical Monitoring and Nutritional Support
Study NCT05508204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BION-1301
Description: A solution for SC injection administered as a single dose
Study NCT02172001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000
Study NCT02172001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natrium Chloride 0,9%
Description: 100 ml or 5 ml
Study NCT06311305 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Early Laparoscopic cholecystectomy
Description: laparoscopic cholecystectomy early after ERCP with assessing the risks and complications
Study NCT04902183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CovenD24
Description: The drug will be administrated once daily for 5 days
Study NCT06546722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Thoracic Plane Block
Description: The Transversus Thoracic Plane Block is a recent regional anesthesia technique. It provides analgesia for the anterior cutaneous branches of the intercostal nerves T2-6 to the medial anterior chest wall via a single injection of local anesthesia between the internal intercostal muscle and the transversus thoracic muscle located between the third and fourth (or fourth and fifth) intercostal space. It is noteworthy that the TTPB can consequently reduce pulmonary morbidity and the need for high-dose opioids.
Study NCT05132894 — intervention group
Intervention type: OTHER
Intervention: Osteopathic Assessment
Description: As osteopathic structural exam will be performed to assessment somatic dysfunctions of the lower extremities.
Study NCT05353777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levita Robotic Platform
Description: Levita Robotic Platform
Study NCT05250427 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study NCT06415097 — intervention group
Intervention type: DEVICE
Intervention: Insulin Smart Pen
Description: Retrospective analysis of electronic health records for individuals with type 1 diabetes receiving multiple daily doses of insulin, combined with glucose monitoring devices and who have used or are currently using insulin smart pens.
Study NCT04309695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenflow Spring System
Description: The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
Study NCT04923347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: FF/UMEC/VI will be administered
Study NCT04923347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Participants will receive FF/UMEC/VI using ELLIPTA inhaler.
Study NCT05442268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acetaminophen group
Description: patients will receive intravenous 500 mg acetaminophen(every 6 hours postoperatively
Study NCT05442268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duloxetine group
Description: Patients will receive duloxetine 30 mg every 12 hours for 3 days before surgery, 30 mg 2 hours preoperatively and 30 mg 12 hours postoperatively and intravenous 500 mg acetaminophen every 6 hours postoperatively
Study NCT05472064 — intervention group
Intervention type: OTHER
Intervention: Persona: Primary care doctor
Description: The chatbot persona is a Black woman who is a primary care doctor.
Study NCT06345391 — intervention group
Intervention type: OTHER
Intervention: Co-creation
Description: Participatory approach maximally and directly involving important stakeholders (bottom-up) to co-create a pain science education intervention for children living beyond cancer.
Study NCT06345391 — intervention group
Intervention type: OTHER
Intervention: Concept Mapping
Description: Concept mapping to create a pain science education intervention for children living beyond cancer.
Study NCT05472064 — intervention group
Intervention type: OTHER
Intervention: Persona: Breast cancer survivor
Description: The chatbot persona is a Black woman who is a breast cancer survivor.
Study NCT05472064 — intervention group
Intervention type: OTHER
Intervention: Communication Style: Direct
Description: The chatbot messages are characterized by commands and direct addresses (''you'').
Study NCT05472064 — intervention group
Intervention type: OTHER
Intervention: Communication Style: Indirect
Description: The chatbot messages are characterized by subjunctive modal verb forms (''would like'') and cooperative addresses (''we, let's).